Clinical and biomarker predictors of side effects from tamoxifen

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 1107-1118

  Lorizio, Wendy ^a,b   Wu, Alan H B ^a,c   Beattie, Mary S ^a,b,d,e   Rugo, Hope ^a,b,e   Tchu, Simone ^c,d   Kerlikowske, Karla ^a,f   Ziv, Elad ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Breast cancer treatment; Endoxifen; Predictors; Side effects; Tamoxifen

Indexed keywords

AFIMOXIFENE; CYTOCHROME P450 2D6; ENDOXIFEN; ESTROGEN; PROGESTERONE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYP2D6 GENE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HOT FLUSH; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MOOD CHANGE; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; VAGINAL DRYNESS; WEIGHT GAIN; BREAST TUMOR; GENETIC ASSOCIATION; GENETICS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LOGISTIC MODELS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; TAMOXIFEN; YOUNG ADULT;

EID: 84865173799     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1893-4     Document Type: Article

References (54)

1. Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2(3):205-213
2. Group EBCTC (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
3. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH (2003) Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95(7):526-532
4. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, Cailleux PE, Lhomme C (2002) Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer 12(5):496-500
5. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354):296-300
6. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86(7):527-537
7. Hendrick A, Subramanian VP (1980) Tamoxifen and thromboembolism. JAMA 243(6):514-515
8. Love RR, Cameron L, Connell BL, Leventhal H (1991) Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151(9):1842-1847
9. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA (1998) Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 152:396-411
10. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479-484
11. Ganz PA (2001) Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr 30:130-134
12. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17(9):2659-2669
13. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB (2006) Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 12(2):114-122
14. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, La Vasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247):2059-2063
15. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA (2002) Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20(6):1578-1583
16. Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B, Kimmick G, Lovato J, Gordon P, Pandya K, Guttuso T Jr, Barton D, Novotny P (2009) Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 27(17):2831-2837
17. Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108(3):421-426
18. Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatmentemergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143-1148
19. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49(8):2175-2183
20. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758-1764
21. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69(5):1722-1727
22. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85(2):151-159
23. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609-1618
24. Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75(2):305-316
25. Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3):1062-1075
26. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30-39
27. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23(36):9312-9318
28. Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z, Sikora MJ, Philips S, Nguyen AT, Storniolo AM, Hayes DF, Flockhart DA, Stearns V (2009) Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 117(3):571-575
29. Madlensky L, Flatt SW, Natarajan L, Lawrence HJ, Nikoloff DM, Fontecha M, Hao S, Hillman G, Johnson A, Parker BAJPP (2009) Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen. Cancer Res 69(Suppl):6045
30. Leyland-Jones B, Regan MM, Bouzyk M, Kammler R, Tang W, Pagani O, Maibach R, Dell'Orto P, Thurlimann B, Price KN, Viale G; Group B-CGaIBCS (2010) Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. Cancer Res 70(24 Suppl 2):Abstract nr S1-8
31. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89(5):718-725
32. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, Chabert J, Dayer P, Hochstrasser D, Rossier MF (2009) The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 9(1):34-41
33. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83(2):234-242
34. Flockhart DA (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. [http://medicine.iupui.edu/ clinpharm/ddis/tableaspx]
35. Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK (2000) Tamoxifen-induced hot flashes. Clin Breast Cancer 1(1):52-56
36. Perez DG, Zahasky KM, Loprinzi CL, Sloan J, Novotny P, Barton D, Pritchard KI (2007) Tamoxifen-associated hot flashes in women. Support Cancer Ther 4(3):152-156
37. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322-328
38. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Pineda S, Cuzick J, Dowsett M (2010) Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Cancer Res 70(24 Suppl 2):Abstract nr S1-7
39. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1):61-74
40. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28(16):2768-2776
41. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89(5):708-717
42. Fallowfield L (2005) Acceptance of adjuvant therapy and quality of life issues. Breast 14(6):612-616
43. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU (2006) Polymorphism in the CYP2D6 tamoxifenmetabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24(22):3708-3709 author reply 3709
44. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60-62
45. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486-492
46. Staropoli CA, Flaws JA, Bush TL, Moulton AW (1998) Predictors of menopausal hot flashes. J Womens Health 7(9):1149-1155
47. Wilbur J, Miller AM, Montgomery A, Chandler P (1998) Sociodemographic characteristics, biological factors, and symptom reporting in midlife women. Menopause 5(1):43-51
48. Hunter MS (1993) Predictors of menopausal symptoms: psychosocial aspects. Baillieres Clin Endocrinol Metab 7(1):33-45
49. Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, Salamone L, Stellato R (2000) Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 152(5):463-473
50. Freeman EW, Sammel MD, Grisso JA, Battistini M, Garcia-Espagna B, Hollander L (2001) Hot flashes in the late reproductive years: risk factors for Africa American and Caucasian women. J Womens Health Gend Based Med 10(1):67-76
51. Schwingl PJ, Hulka BS, Harlow SD (1994) Risk factors for menopausal hot flashes. Obstet Gynecol 84(1):29-34
52. Brown DE, Sievert LL, Morrison LA, Reza AM, Mills PS (2009) Do Japanese American women really have fewer hot flashes than European Americans? The Hilo Women's Health Study. Menopause 16(5):870-876
53. Avis NE, Stellato R, Crawford S, Bromberger J, Ganz P, Cain V, Kagawa-Singer M (2001) Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 52(3):345-356
54. Sievert LL, Morrison L, Brown DE, Reza AM (2007) Vasomotor symptoms among Japanese-American and European-American women living in Hilo, Hawaii. Menopause 14(2):261-269